.jpg)
Peptris Technologies has made history by licensing India’s first AI-discovered drug candidate, PEPR124 (RT001), to Revio Therapeutics for further development in treating Duchenne Muscular Dystrophy (DMD)—a rare and progressive genetic disorder. This marks a significant leap in AI-powered drug discovery, showcasing the potential of artificial intelligence in revolutionizing therapeutic advancements.
PEPR124 is a repurposed, mutation-agnostic drug that has demonstrated strong preclinical efficacy and a favorable safety profile, making it a Phase 2-ready asset. Revio Therapeutics will lead global commercialization, while Peptris retains rights in BRICS nations. The company also intends to engage with the US FDA for a pre-IND meeting and apply for orphan drug designation to accelerate regulatory approvals.
Beyond PEPR124, Peptris Technologies is actively expanding its AI-driven drug discovery pipeline, focusing on Rare Diseases, Alopecia, Inflammation, and Oncology. By integrating advanced AI algorithms, the company is committed to delivering innovative and accessible treatments for unmet medical needs.
This breakthrough underscores India’s growing leadership in AI-driven healthcare innovation, setting the stage for faster, cost-effective drug discovery and development.